Get Support Donate Follow Us Get Involved

Fall 2019

Dear Voornaam,

You are receiving this email because you signed up for FORCE’s Research Interest List. We will send you information quarterly on cancer prevention, detection, treatment and quality of life research studies enrolling people with hereditary cancer and provide updates on new research findings.

Research Spotlight: Energetics and Lifestyle in Inherited Syndromes (ELLIE's Study)

Researchers at the University of Kansas are studying the lifestyle factors that may affect cancer risk in people with inherited mutations linked to cancer. The study will look at weight, Body Mass Index, metabolism, dietary habits and activity level over the course of people’s life time. Men or women with a mutation in any of the following genes are invited to participate in this study: APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN4, CHEK2, DICER1, EPCAM, GREM1, HOXB13, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMAD4, SMARCA4, STK11 or TP53.

ELLIE’s study is a web-based survey. It is open to eligible people who have a personal email and internet access.

The web-based survey can be accessed through this hyperlink. Then enter the code: PYCYHXD3A

The first 1,000 participants will receive a $10.00 e-gift card. The e-gift card will be delivered by email.

Find and Enroll in Hereditary Cancer Studies!

Behind the Headlines: Promising Research on PARP Inhibitors for Early-Stage Breast Cancer

PARP inhibitors have been useful for the treatment of advanced or metastatic breast cancer in people with a BRCA mutation. A study showed that the patients who took the PARP inhibitor talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result.

Read Our XRAY Review

Clinical Trials and Research Studies Need Participants

Read about hereditary cancer research studies and visit our Featured Research Page and our HBOC Research Study Search Tool for additional prevention, detection, treatment, and genetics research studies.

Athena- Rucaparib and Novolumab for Maintenance in Ovarian Cancer

ATHENA is a study for women who are newly diagnosed with ovarian cancer. ATHENA is looking at whether maintenance therapy with a PARP inhibitor and/or immunotherapy improves outcomes for women who have completed front-line ovarian cancer treatment.

Learn More About ATHENA

TRITON2- Prostate Cancer

The purpose of TRITON2 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited gene mutation or tumor genetic deficiency respond to treatment with the PARP inhibitor rucaparib (Rubraca).

More Information on TRITON2

TRITON3- Prostate Cancer

The purpose of TRITON3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited BRCA1, BRCA2 or ATM gene mutation or tumor genetic deficiency respond to treatment with the PARP inhibitor rucaparib (Rubraca) compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

More Information on TRITON3

Chemotherapy and PARP Inhibitor for Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

This clinical trial studies a combination of drugs to learn the best dose, side effects, and how well they work together for treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body.

Learn More About the Study

Immunotherapy and PARP Inhibitor Combo for Advanced Cancers Caused By a BRCA or ATM Mutation

Researchers want to learn how safe and effective the combination of an immunotherapy (known as Avelumab) and a PARP inhibitor (known as Talazoparib) is for treating patients with locally advanced or metastatic solid tumors with a BRCA1, BRCA2, or ATM gene defect.

Learn More About the Study

GENERATE Study

The GENERATE (GENetic Education Risk Assessment and Testing) Study offers genetic testing for people who have a close relative with pancreatic cancer that was caused by a mutation in a gene. Knowing about inherited risk helps families protect themselves against pancreatic and other cancers. Visit the study website to learn more and fill out the Eligibility Questionnaire.
Learn More About GENERATE

CheckMate-9KD

CheckMate-9KD is a clinical research study for men with metastatic prostate cancer (which means cancer that has spread) that no longer responds to treatments that lower testosterone. Visit the link below to learn more about the study.

Learn More About CheckMate-9K

Metastatic Prostate Cancer Project

The Metastatic Prostate Cancer Project is a nationwide genomic research study for men with advanced and/or metastatic prostate cancer. Patients can join online and participate by sharing their medical information and samples. The goal of the project is to generate a comprehensive database that will be shared with the entire research community to accelerate discoveries in prostate cancer.

Learn More About the Study

Menopause and Cognitive Difficulty Study

Did you know undergoing surgically or chemically induced menopause could put you at risk for cognitive difficulties? Our study seeks to determine the effectiveness of a stimulant drug called Vyvanse on the cognitive functioning of women who experience executive functioning difficulties following surgically induced menopause. For more information, please contact our team.

Learn More About IMPRES

A Study in Advanced Breast Cancer Patients With BRCA 1/2 Mutations Evaluating Olaparib Alone or In Combination With Atezolizumab

This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of this study is to look at whether giving the DNA damage repair inhibitor (PARP inhibitor) olaparib (Lynparza) in combination with the immunotherapy atezolizumab (Tecentriq) improves outcomes for patients compared to olaparib alone.
Learn More About the Study

Olaparib Expanded Study – Metastatic Breast Cancer

The Olaparib Expanded study is enrolling people with metastatic breast cancer who do not have an inherited BRCA mutation. The study is looking at olaparib to treat metastatic breast cancer in people with non-BRCA inherited mutations, such as PALB2, ATM, CHEK2, BRIP1 and others. The study is also open to people with BRCA or other mutations within their tumor.
Learn More About the Study

Ovarian Cancer Treatment Preferences Survey

If you have ever been diagnosed with Ovarian, Fallopian Tube, or Primary Peritoneal cancer and have undergone chemotherapy, please consider participating in this Patient Preferences Study. Our goal is to learn about what is most important to patients when choosing cancer treatment. Specifically, we'd like to know how patients feel about taking a break from treatment versus taking an additional medication.

Click Here to Begin the Survey

GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer

The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.

This study involves undergoing genetic counseling and genetic testing for inherited cancer risk.

Learn More About the Study

Genetic Education for Men (GEM) Study

The Genetic Education for Men (GEM) study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative.
Learn More About the GEM Study

ARIEL4- Ovarian Cancer

ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information.
More Information on ARIEL4

BRCA Founder Outreach Study (BFOR)

BFOR is a research project led by experts in cancer genetics to study a new way to make genetic testing accessible. It offers BRCA testing at no cost to individuals age 25 or older, with at least one Ashkenazi Jewish grandparent, and who live in the Boston, New York, Los Angeles or Philadelphia metropolitan areas.

Learn More About BFOR

Metastatic Breast Cancer Project

The Metastatic Breast Cancer Project is a patient-partnered initiative that directly engages patients across the US & Canada to transform our understanding of metastatic breast cancer. Patients participate by sharing their medical information, tumor samples, and their voices. There is no cost to participate. A small effort can have a major impact.

Learn More About the Study

WISP - Women Choosing Surgical Prevention

This study is open to pre-menopausal women between 30-50 with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, PMS2 or EPCAM. Women choose to either have their fallopian tubes removed now and their ovaries later or to have their tubes and ovaries removed at the same time. Outcomes are sexual function and quality of life between the women grouped by surgical procedure.

Learn More About WISP

MAGENTA (MAking GENetic Testing Accessible)

The MAGENTA study is open to women 30 years of age or older who may be at increased risk to develop ovarian cancer based on their personal or family history. Participants who qualify for this study will undergo genetic testing (using a saliva sample) for 19 genes associated with inherited cancer risk (including BRCA1 and BRCA2), and complete a series of online questionnaires regarding their experience. Some individuals in this study will undergo genetic counseling over the phone; others will not. Participation in this trial will not require any travel, but will require access to the internet and phone.

Learn More About MAGENTA

FORCE®, FORCE FACING OUR RISK OF CANCER EMPOWERED®, JOINING FORCE AGAINST HEREDITARY CANCER®, PREVIVOR®, and the FORCE Ribbon Design are registered trademarks of FORCE- Facing Our Risk of Cancer Empowered, Inc. in the United States. Unauthorized reproduction or use of FORCE's trademarks is prohibited.